llian
Member
- Joined
- Dec 23, 2020
- Messages
- 198
This isn't anything new and this diuretic is used for some time to treat autism and neurological disorders like it.
Bumetanide The diuretic bumetanide, a chloride-importer antagonist, targets abnormalities in intracellular GABAA chloride levels
Symptom improvement in children with autism spectrum disorder following bumetanide administration is associated with decreased GABA/glutamate ratios
"In the first single-center trial, 60 children with ASD received 1 mg of bumetanide daily for 3 months. Bumetanide improved scores on the CARS but the ADOS Reciprocity subscale did not improve [140]. In a large (n = 80), six-center 3-month DBPC with three doses (0.5 mg, 1.0 mg, or 2.0 mg twice daily), bumetanide improved scores on the CARS and SRS [141]. The treatment was well tolerated in these trials with some patients showing mild hypokalemia requiring potassium supplementation."
"Two studies measured biomarkers of social cognition during open-label bumetanide treatment. Ten months of bumetanide treatment in adolescents and young adults (n = 7) improved emotion recognition and enhanced activation in social and emotional perception areas of the brain during the viewing of emotional faces [142]. In a study on the same population plus two additional participants (n = 9), bumetanide normalized amygdala activation during a constrained eye contact task and increased the time spent looking at the eyes in face stimuli [143]."
The only side effect from it was Potassium depletion since it is an diuretic and long term usage of it can lead to hypokalemia, as seen in the study. This can be avoided by using supplemental potassium with it.
Seems like the typical dosage for this was 0.5 mg twice daily.
@haidut what you think about this?
Bumetanide The diuretic bumetanide, a chloride-importer antagonist, targets abnormalities in intracellular GABAA chloride levels
Symptom improvement in children with autism spectrum disorder following bumetanide administration is associated with decreased GABA/glutamate ratios
"In the first single-center trial, 60 children with ASD received 1 mg of bumetanide daily for 3 months. Bumetanide improved scores on the CARS but the ADOS Reciprocity subscale did not improve [140]. In a large (n = 80), six-center 3-month DBPC with three doses (0.5 mg, 1.0 mg, or 2.0 mg twice daily), bumetanide improved scores on the CARS and SRS [141]. The treatment was well tolerated in these trials with some patients showing mild hypokalemia requiring potassium supplementation."
"Two studies measured biomarkers of social cognition during open-label bumetanide treatment. Ten months of bumetanide treatment in adolescents and young adults (n = 7) improved emotion recognition and enhanced activation in social and emotional perception areas of the brain during the viewing of emotional faces [142]. In a study on the same population plus two additional participants (n = 9), bumetanide normalized amygdala activation during a constrained eye contact task and increased the time spent looking at the eyes in face stimuli [143]."
The only side effect from it was Potassium depletion since it is an diuretic and long term usage of it can lead to hypokalemia, as seen in the study. This can be avoided by using supplemental potassium with it.
Seems like the typical dosage for this was 0.5 mg twice daily.
Bumetanide Therapeutic Effect in Children and Adolescents With Autism Spectrum Disorder: A Review Study
Autism Spectrum Disorder (ASD) is characterized by several impairments in communications and social interactions, as well as restricted interests or stereotyped behaviors. Interventions applied for this disorder are based on multi-modal approaches, including ...
www.ncbi.nlm.nih.gov
Bumetanide for Core Symptoms of Autism Spectrum Disorder (BAMBI): A Single Center, Double-Blinded, Participant-Randomized, Placebo-Controlled, Phase-2 Superiority Trial - PubMed
Bumetanide in Autism Medication and Biomarker Study (BAMBI); https://www.clinicaltrialsregister.eu/; 2014-001560-35.
pubmed.ncbi.nlm.nih.gov
@haidut what you think about this?